Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study

D. Miller, Paul; R. McClung, Michael; Macovei, Liviu; A. Stakkestad, J.; M. Luckey, Marjorie; Bonvoisin, Bernard; Reginster, Jean‐Yves; R. Recker, Robert; Hughes, Claire; Michael Lewiecki, E.; Felsenberg, Dieter; D. Delmas, Pierre; L. Kendler, David; A. Bolognese, Michael; Mairon, Nicole; Cooper, Cyrus

doi:10.1359/jbmr.050313

Public

Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study

Published in Journal of Bone and Mineral Research • Aug 1, 2005

Authors:

Paul D. Miller

Michael R. McClung

Liviu Macovei

Abstract

UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTROD...

Subject

Medicine

Tolerability

Regimen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!